Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT03931551
Title Olaparib+Trastuzumab in HER2[+],Breast Cancer Susceptibility Gene (BRCA) Mutated Advanced Breast Cancer (OPHELIA)
Acronym OPHELIA
Recruitment Terminated
Gender both
Phase Phase II
Variant Requirements No
Sponsors MedSIR
Indications
Therapies
Age Groups: senior | adult
Covered Countries ESP


No variant requirements are available.